BU-NOT-SET

CONTACT US
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
White paper
  • Biologics
Product Quality in the Advanced Therapies Manufacturing
Insight
  • Biologics
Navigating ATMP fill and finish complexities
Insight
  • Biologics
The power of analytics and AI in the era of continuous RNA manufacturing
Insight
  • Biologics
Reimagining the RNA manufacturing space: An interview with ReciBioPharm’s leaders
Insight
  • Biologics
Unlocking the potential of mRNA: Inside ReciBioPharm's Watertown site
Insight
  • Biologics
Industry 5.0 in action: AI-driven continuous manufacturing for RNA therapeutics
Insight
  • Drug product
  • Manufacturing
Choosing the optimal container format for sterile drug products
Insight
  • Manufacturing
FDA inspection success at Recipharm’s site in Bengaluru, India
Fact sheet
  • Drug product
  • Manufacturing
Lyophilisation Services